1 | learn more synergia medical | | | | | | | 3 | 1.05% |
2 | increases series b funding | | | | | | | 2 | 0.70% |
3 | galien in belgium for | | | | | | | 2 | 0.70% |
4 | in belgium for its | | | | | | | 2 | 0.70% |
5 | belgium for its optoelectronic | | | | | | | 2 | 0.70% |
6 | an additional €38 million | | | | | | | 2 | 0.70% |
7 | with an additional €38 | | | | | | | 2 | 0.70% |
8 | synergia medical increases series | | | | | | | 2 | 0.70% |
9 | medical increases series b | | | | | | | 2 | 0.70% |
10 | toggle navigation synergia medical | | | | | | | 1 | 0.35% |
11 | prix galien in belgium | | | | | | | 1 | 0.35% |
12 | for its optoelectronic neurostimulator | | | | | | | 1 | 0.35% |
13 | its optoelectronic neurostimulator january | | | | | | | 1 | 0.35% |
14 | optoelectronic neurostimulator january 18 | | | | | | | 1 | 0.35% |
15 | 2023 synergia medical increases | | | | | | | 1 | 0.35% |
16 | funding to €128 million | | | | | | | 1 | 0.35% |
17 | series b funding to | | | | | | | 1 | 0.35% |
18 | b funding to €128 | | | | | | | 1 | 0.35% |
19 | medical wins prestigious prix | | | | | | | 1 | 0.35% |
20 | to €128 million with | | | | | | | 1 | 0.35% |
21 | €128 million with an | | | | | | | 1 | 0.35% |
22 | million with an additional | | | | | | | 1 | 0.35% |
23 | additional €38 million drug | | | | | | | 1 | 0.35% |
24 | €38 million drug resistant | | | | | | | 1 | 0.35% |
25 | million drug resistant epilepsy | | | | | | | 1 | 0.35% |
26 | synergia medical obtains belgium | | | | | | | 1 | 0.35% |
27 | medical obtains belgium health | | | | | | | 1 | 0.35% |
28 | obtains belgium health authority | | | | | | | 1 | 0.35% |
29 | prestigious prix galien in | | | | | | | 1 | 0.35% |
30 | synergia medical wins prestigious | | | | | | | 1 | 0.35% |
31 | health authority approval to | | | | | | | 1 | 0.35% |
32 | navigation synergia medical logo | | | | | | | 1 | 0.35% |
33 | synergia medical’s current ip | | | | | | | 1 | 0.35% |
34 | medical’s current ip portfolio | | | | | | | 1 | 0.35% |
35 | current ip portfolio includes | | | | | | | 1 | 0.35% |
36 | nonmetallic encapsulation of neurostimulators | | | | | | | 1 | 0.35% |
37 | encapsulation of neurostimulators fastcharging | | | | | | | 1 | 0.35% |
38 | of neurostimulators fastcharging wireless | | | | | | | 1 | 0.35% |
39 | system a custom optical | | | | | | | 1 | 0.35% |
40 | a custom optical lead | | | | | | | 1 | 0.35% |